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Introduction
ST-segment elevation myocardial infarction (STEMI) is a con-
sequence of atherosclerotic plaque rupture and thrombotic oc-
clusion of the coronary artery causing downstream ischaemia
and, eventually, cell death. The most effective therapeutic strat-
egy for STEMI is timely reperfusion by primary percutaneous
coronary intervention (PPCI). Such reperfusion is a prerequi-
site for myocardial salvage, leading to smaller infarct sizes and
improved clinical outcomes [1, 2]. However, reperfusion can
itself inflict further injury, termed ischaemia-reperfusion injury
(IRI). Despite PPCI, a recent study found 30-day, 1-year, and
5-year mortality following STEMI to be 7.9 %, 11.4 %, and
23.3 %, respectively [3]. Consequently, novel strategies to mit-
igate the deleterious effects of IRI are paramount.
Stromal derived factor-1α (SDF-1α or CXCL12) is a che-
mokine that has demonstrated cardioprotective activity in
mice [4]. We recently demonstrated that exogenous SDF-1α
improved functional recovery of ex vivo rat cardiac papillary
muscle subjected to hypoxia and reoxygenation (simulated
IRI) [5]. This effect was abrogated by pre-treatment with
AMD3100, a highly specific antagonist of the SDF-1α recep-
tor, CXCR4.
However, it is not known whether SDF-1α can similarly
protect human heart tissue and whether any such protection is
afforded via CXCR4. We address this question using isolated
human atrial trabeculae subjected to simulated IRI.
Methods
Human Atrial Trabeculae Hypoxia-Reoxygenation
Experiments
The study received Local Research Ethics Committee approv-
al and was carried out in accordance with the University
College London Hospitals NHS Trust guidelines. A right atri-
al appendage sample was harvested from 47 patients with
chronic stable angina undergoing cannulation for cardiopul-
monary bypass for CABG.All patients were aged 18–80 years
and there were no significant differences in their baseline
characteristics (see Table 1). Patients with diabetes, impaired
renal or ventricular function, dilated left atria, unstable angina,
or a history of arrhythmias or on rhythm stabilising medica-
tions were excluded.
Trabeculae were randomly allocated to [1] control (n = 11),
[2] hypoxic preconditioning (n = 10), [3] SDF-1α pre-treat-
ment (n = 11), [4] AMD3100 + SDF-1α pre-treatment
(n = 10), and [5] AMD3100 pre-treatment (n = 5). Two sep-
arate trabeculae were collected for immunofluorescent stain-
ing. The sample was placed in ice-cold buffer prior to careful
dissection of the trabeculae. Isolated trabeculae (≤1.2 mm in
diameter and ≥2.0 mm in length) were suspended in a heated
(37 °C) organ bath with one end connected to a force trans-
ducer. Samples were superfused with oxygenated modified
Tyrode’s buffer (95 % O2/5 % CO2) at 37 ± 0.5 °C and
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pH 7.4 ± 0.5 [5]. The muscle was electrically paced at 1 Hz
and stretched until the maximum force of contraction (the
peak of the Frank-Starling curve) was achieved. The muscle
was subsequently allowed to stabilise for 90 min before being
subjected to 60 min of hypoxia by superfusion with
equiosmolar, glucose-free hypoxic modified Tyrode’s buffer
(95 % N2/5 % CO2), pH 7.4 ± 0.5 and electrical stimulation at
3 Hz. Themuscle was reoxygenated for 60min with normoxic
buffer and 1 Hz stimulation, to simulate reperfusion. Hypoxic
preconditioning, consisting of 4.5 min hypoxia and pacing at
3 Hz followed by 6 min reoxygenation and pacing at 1 Hz,
was applied immediately prior to the index hypoxic period as
a positive cardioprotective control [5]. SDF-1α (25 ng/ml),
AMD3100 (10 μg/ml) or saline vehicle were administered
for 30 min and 40 min respectively prior to index hypoxia,
concentrations that were based on previous publications [4, 5].
Immunohistochemistry
In a separate group of experiments, isolated human atrial tra-
beculae were frozen and mounted in OCT before being cut
into 5 μm sections at −20°C in a microtome-cryostat and
transferred to slides. Sections were fixed with HistoChoice
(Sigma-Aldrich, UK) for 20 min at room temperature and
washed with PBS, before blocking with 5 % BSA/PBS for
60 min. Immunofluorescent co-staining of CXCR4 and
cardiomyocytes was performed using rabbit monoclonal
anti-CXCR4 (ab124824) and mouse anti-cardiac troponin T
(ab8295) from Abcam (Gillingham, UK). Anti-rabbit Alexa
Fluor 488 and anti-mouse Alexa Fluor 555 secondary antibod-
ies were purchased from Abcam. Cardiomyocyte co-stained
samples were incubated in anti-CXCR4 and anti-cardiac tro-
ponin T, diluted in 1 % BSA/PBS 1:100 and 1:10 respectively,
overnight at 4°C. Following washing and incubation with the
appropriate secondary antibody diluted 1:400 in the same
buffer for 60 min at room temperature, samples were washed
again and coverslips mounted using fluorescence mounting
medium (Dako, Ely, UK). 0.1 μg/ml Hoechst 33,258 nuclear
stain (Life Technologies, Paisley, UK) was added with the
secondary antibodies to all sections. Preparation of control
sections was identical and they were incubated either with
1 % BSA/PBS only (unstained control) or with the relevant
secondary antibody in the absence of any primary antibody.
After drying, Alexa 488 and Alexa 555 fluorescence was











Mean age (years) 61 64.8 64.6 63.4 61.6
Gender (male) 9 (82 %) 10 (100 %) 10 (91 %) 7 (70 %) 4 (80 %)
Good LV (>50 %) 11 (100 %) 10 (100 %) 11 (100 %) 10 (100 %) 5 (100 %)
eGFR >55 mL/min 11 (100 %) 10 (100 %) 11 (100 %) 10 (100 %) 5 (100 %)
Rhythm
Sinus 11 (100 %) 10 (100 %) 11 (100 %) 10 (100 %) 5 (100 %)
Surgery
CABG 7 (64 %) 4 (40 %) 7 (64 %) 5 (50 %) 1 (20 %)
AVR 4 (36 %) 5 (50 %) 0 (0 %) 5 (50 %) 4 (80 %)
CABG + AVR 0 (0 %) 1 (10 %) 4 (36 %) 0 (0 %) 0 (0 %)
Medications
β-blocker 8 (73 %) 4 (40 %) 7 (64 %) 2 (20 %) 1 (20 %)
ACE inhibitor 5 (45 %) 5 (50 %) 5 (45 %) 3 (30 %) 1 (20 %)
Calcium channel blocker 2 (18 %) 0 (0 %) 1 (9 %) 1 (10 %) 1 (20 %)
Nitrate 2 (18 %) 2 (20 %) 1 (9 %) 1 (10 %) 1 (20 %)
Statin 8 (73 %) 2 (20 %) 7 (64 %) 5 (50 %) 3 (60 %)
MRA 1 (9 %) 1 (10 %) 0 (0 %) 0 (0 %) 0 (0 %)
Diuretic 2 (18 %) 1 (10 %) 1 (9 %) 0 (0 %) 0 (0 %)
Anti-arrhythmic 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Trabecular dimensions
Length (mm) 4.31 5.16 5.05 3.86 4.6
Diameter (mm) 0.97 1.01 1.09 1.18 0.89
LV, left ventricle; eGFR, estimated glomerular filtration rate; CABG, coronary artery bypass graft surgery; AVR, aortic valve replacement; ACE,
angiotensin converting enzmye; MRA, mineralocorticoid receptor antagonist
*Data expressed as number (%) or mean
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imaged using a 40× oil immersion objective, by sequential
scanning using the 488 nm and 543 nm lines of a Leica SP5
confocal microscope and collecting emitted light at 500–
530 nm and 580–650 nm respectively. Control experiments
were performed to confirm the absence of fluorescence bleed-
through or non-specific staining with secondary antibodies
alone.
Statistics
The final force of contraction in the human atrial trabeculae
hypoxia-reoxygenation experiments was expressed as a
percentage of baseline contractility to give recovery of function.
Values are expressed as mean ± SEM. Comparisons between
more than 2 groups were made using 1-way analysis of variance
(ANOVA). Fisher’s protected least significant difference post
hoc test was used for between-group comparisons. Differences
were considered statistically significant when P < 0.05.
Results
In control trabeculae, the mean recovery of function after hyp-
oxia and reoxygenation was 27 ± 2 % [1]. Recovery of
Fig. 1 The SDF-1α-CXCR4 axis
protects humanmyocardium from
hypoxia-reoxygenation injury: a
Recovery of contractile function
during simulated ischaemia and
reperfusion applied to isolated
human atrial trabeculae is
improved by pre-treatment with
exogenous SDF-1α to a level
similar to that conferred by
hypoxic preconditioning. N = 11
atrial trabeculae in the control and
SDF-1α pre-treatment groups, 10
in the hypoxic preconditioning
and AMD3100 + SDF-1α pre-
treatment groups, and 5 in the
AMD3100 pre-treatment group.
*SDF-1α vs. control, †AMD +
SDF-1α vs. SDF-1α (*P < 0.05,
**P < 0.005, ***P < 0.001). b,
Immunofluorescent staining of
isolated human atrial trabeculae
demonstrating the distribution of
CXCR4 (green) in relation to
cardiomyocytes (red). c,
Immunofluorescent staining
using secondary antibody in the
absence of primary antibody.
Representative images fromN = 2
independent experiments, 50 μm
scale bar
Cardiovasc Drugs Ther (2015) 29:589–592 591
function in samples pre-treated with SDF-1αwas significantly
increased (53 ± 3 %, P < 0.05 vs. control, Fig. 1), which was
similar to that in control trabeculae subjected to hypoxic pre-
conditioning (48 ± 4 %, P < 0.05 vs. control).
The role of signalling via CXCR4 was investigated by pre-
treating trabeculae with the specific CXCR4 inhibitor,
AMD3100, which abrogated the protective effect of SDF-1
(30 ± 2 %, P < 0.05 vs. SDF-1α alone). AMD3100 alone had
no effect on functional recovery (25 ± 4 %). Furthermore,
immunofluorescent staining confirmed the presence of
CXCR4 receptors on cardiomyocytes in human atrial trabec-
ulae (Fig. 1).
Discussion
SDF-1α is a small CXC chemokine that is expressed by sev-
eral organs and tissues, including endothelial cells and
cardiomyocytes in the heart [6]. Its cognate receptors
CXCR4 and CXCR7 are similarly present in a range of tis-
sues, including cardiomyocytes. The SDF-1α/CXCR4 axis
has garnered considerable interest due to its role in stem cell
homing, angiogenesis and ventricular remodelling after myo-
cardial infarction, and has been used to target stem cells to
ischaemic tissue, thereby improving LV dimensions and func-
tion [7].
We and others have previously demonstrated a
cardioprotective role for SDF-1α on both infarct size in iso-
lated perfused rat hearts and recovery of function in isolated
rat papillary muscle [5, 8]. Both of these beneficial effects
were abolished by AMD3100, all of which evidences a
cardioprotective role for the SDF-1α/CXCR4 axis.
Elsewhere, the application of exogenous SDF-1 has been
shown to reduce apoptosis in isolated cardiomyocytes and
SDF-1 infused into the murine LV cavity in vivo produced
significantly smaller infarct sizes after IRI, both effects that
were abrogated by AMD3100 [9].
This ex vivo functional model of hypoxia and reoxygena-
tion translates the aforementioned findings to human myocar-
dium for the first time, in the native milieu of the functional
heart. This study confirms [1] the ability of exogenous SDF-
1α to protect human atrial trabeculae from the detrimental
effects of simulated IRI; [2] the role of CXCR4 in this mech-
anism, as evidenced by attenuating the benefits of SDF-1α
using the specific receptor blocker AMD3100; and [3] the
presence and distribution of CXCR4 in human adult
cardiomyocytes and endothelial cells.
There is evidence that the cardioprotective utility of SDF-
1α/CXCR4 may be conferred by activating intracellular pro-
survival kinases, although the specific mechanism remains
unknown [5]. However, it is thought to converge on the mito-
chondrial permeability transition pore (mPTP) and effect
protection by delaying its opening and consequent necrotic
cell death [10]. The exact mechanism of protection afforded
by SDF-1α/CXCR4 should be the focus of further investiga-
tion in both basic and clinical studies.
In summary, our findings support the hypothesis that exog-
enous SDF-1α is a preconditioning mimetic, herein shown to
exert acute protection against the deleterious effects of hypox-
ia and reoxygenation and that this protection, in the isolated
human atrial trabeculae, occurs via the CXCR4 receptor.
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